<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635189</url>
  </required_header>
  <id_info>
    <org_study_id>UMMY20033</org_study_id>
    <nct_id>NCT04635189</nct_id>
  </id_info>
  <brief_title>Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of daratumumab and lenalidomide without&#xD;
      steroids for treating patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, phase 2 study consisting of daratumumab, lenalidomide and&#xD;
      dexamethasone, given upfront in newly diagnosed, transplant ineligible patients with myeloma.&#xD;
      Patients participating in the study will be recruited from the Wilmot Cancer Institute,&#xD;
      University of Rochester in Rochester, New York and all University of Rochester community&#xD;
      affiliates.&#xD;
&#xD;
      Patients will be treated with 1800 milligrams of Daratumumab subcutaneously or 16&#xD;
      milligrams/kilograms daratumumab intravenously (IV) weekly for 8 treatments, followed by&#xD;
      every 2 weeks for 8 treatments, followed by every 4 weeks. Patients will be treated with 25&#xD;
      milligrams of Lenalidomide days 1-21 out of a 28 day cycle (dose adjustments for creatinine&#xD;
      clearance) and 20 milligrams of Dexamethasone at least 60 minutes prior to first infusion of&#xD;
      daratumumab. Each cycle consists of 28 days (4 weeks).&#xD;
&#xD;
      Response assessments by International Myeloma Working Group criteria for myeloma will be&#xD;
      performed every 4 weeks while on therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daratumumab Related Infusion Reactions</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the rate of daratumumab related infusion reactions in patients treated for myeloma without steroids compared to historical controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Response Rates</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the proportion of patients who do not achieve at least a partial response after 4 cycles and require steroids to be added back to their regimen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm: Cycle 1-4 All subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated with the following:&#xD;
Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks&#xD;
Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle&#xD;
Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm: Cycle 5+ Partial Response or Better</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated the following:&#xD;
Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks&#xD;
Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm: Cycle 5+ Less than Partial Response</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated the following:&#xD;
Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks&#xD;
Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle&#xD;
Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks</description>
    <arm_group_label>Experimental Arm: Cycle 1-4 All subjects</arm_group_label>
    <arm_group_label>Experimental Arm: Cycle 5+ Less than Partial Response</arm_group_label>
    <arm_group_label>Experimental Arm: Cycle 5+ Partial Response or Better</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle</description>
    <arm_group_label>Experimental Arm: Cycle 1-4 All subjects</arm_group_label>
    <arm_group_label>Experimental Arm: Cycle 5+ Less than Partial Response</arm_group_label>
    <arm_group_label>Experimental Arm: Cycle 5+ Partial Response or Better</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab</description>
    <arm_group_label>Experimental Arm: Cycle 1-4 All subjects</arm_group_label>
    <arm_group_label>Experimental Arm: Cycle 5+ Less than Partial Response</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma with diagnosis&#xD;
&#xD;
          -  Must not have received previous therapy for multiple myeloma&#xD;
&#xD;
          -  Newly diagnosed and not considered candidate for high-dose chemotherapy&#xD;
&#xD;
          -  Adequate organ system function&#xD;
&#xD;
          -  A performance status ≤ 3&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
          -  Female subjects of child bearing potential must be surgically sterile, be&#xD;
             post-menopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of primary amyloidosis; monoclonal gammopathy of undetermined&#xD;
             significance, smoldering multiple myeloma; non-secretory myeloma&#xD;
&#xD;
          -  A diagnosis of Waldenström's disease&#xD;
&#xD;
          -  Receiving cancer therapy&#xD;
&#xD;
          -  Radiation therapy within 14 days of enrollment&#xD;
&#xD;
          -  Major surgery within 2 weeks before enrollment&#xD;
&#xD;
          -  Human immunodeficiency virus -infected patients must be on effective anti-retroviral&#xD;
             therapy with undetectable viral load within the past 6 months&#xD;
&#xD;
          -  Seropositive for hepatitis B, or seropositive for hepatitis C&#xD;
&#xD;
          -  Ongoing systemic bacterial, fungal or viral infection&#xD;
&#xD;
          -  Severe and/or uncontrolled medical conditions&#xD;
&#xD;
          -  Malignancy within 2 years of study enrollment&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Contraindications to required prophylaxis for deep vein thrombosis and pulmonary&#xD;
             embolism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Passero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Metzger</last_name>
    <phone>(585)276-7078</phone>
    <email>Lisa_Metzger@URMC.Rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maureen Nealon</last_name>
    <phone>(585) 275-9475</phone>
    <email>Maureen_Nealon@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Passero</last_name>
      <phone>585-275-5863</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Frank Passero</investigator_full_name>
    <investigator_title>Professor of Hematology/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data collected during the trial will be shared after deidentification, including dictionaries.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data for any type of analyses.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

